Tagomics was launched in July 2020, as a spin-out from the University of Birmingham, and is a platform for comprehensive disease insight and diagnosis.

The company combined “omics” technologies, including genomics (detecting mutations), epigenomics (studying chemical ‘switches’ on the genome), and fragmentomics (the analysis of DNA fragmentation patterns in the blood). By integrating these methods and applying advanced data analysis and machine learning, the platform can help discover new markers of cancer and develop strategic partnerships, advancing drug development and therapy selection for patients.